1 drug(s) with this reaction
238 total reports
Acute Lymphocytic Leukaemia has been reported as an adverse reaction across 1 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 238 adverse event reports mention acute lymphocytic leukaemia in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with acute lymphocytic leukaemia, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have acute lymphocytic leukaemia listed in their FDA adverse event reports, sorted by report count:
In addition to acute lymphocytic leukaemia, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
1 drug(s) manufactured by Amgen Inc have acute lymphocytic leukaemia listed in their FDA adverse event reports: BLINATUMOMAB.
There are a combined 238 reports of acute lymphocytic leukaemia across 1 Amgen Inc drug(s) in the FDA adverse event database.